Association Between Apolipoprotein E4 and Cognitive Decline in Elderly Adults

Leiden University, Leyden, South Holland, Netherlands
Journal of the American Geriatrics Society (Impact Factor: 4.57). 11/2007; 55(11):1777-85. DOI: 10.1111/j.1532-5415.2007.01415.x
Source: PubMed


To determine the influence of apolipoprotein E on cognitive decline in a cohort of elderly men and women.
Prospective study.
Scotland, Ireland, and the Netherlands.
Five thousand eight hundred four subjects aged 70 to 82 from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Subjects were assessed at baseline and over a mean 3.2-year (range 0.7-4.2) follow-up for memory (Picture-Word Recall), speed of information processing (Stroop and Letter-Digit Coding), global cognitive function (Mini-Mental State Examination), and activities of daily living.
At baseline, subjects with apolipoprotein E(4) versus those without E(4) had poorer memory performance (mean score difference -0.20 (95% confidence interval (CI)=-0.31 to -0.09) for immediate recall and -0.32 (95% CI=-0.48 to -0.16) for delayed recall and slower information processing (difference in Stroop, 2.79 seconds, (95% CI=1.20-4.28); Letter-Digit score, -0.36, (95% CI=-0.77-0.05). Subjects with apolipoprotein E(4) showed a greater decline in immediate (-0.22, 95% CI=-0.33 to -0.11) and delayed (-0.30, 95% CI=-0.46 to -0.15) memory scores but no significant change in speed of information processing (Stroop, P=.17; Letter-Digit, P=.06). Memory scores decreased 2.5% from baseline in those without E(4), 4.3% in E(4) heterozygotes (P=.01 for immediate and P=.03 for delayed, vs no E(4)) and 8.9% to 13.8% in E(4) homozygotes (P=.04 for immediate and P=.004 for delayed, vs heterozygotes). Apolipoprotein E(4) was associated with greater decline in instrumental activities of daily living (P<.001). Cognitive decline was not associated with lipoprotein levels.
Findings in PROSPER indicate that E(4) is associated with more-rapid cognitive decline and may, therefore, predispose to dementia.

Download full-text


Available from: Brian J Sweeney
  • Source
    • "APOE4 variable was coded to a dichotomous variable as ԑ4 carriers (ԑ2/ԑ4, ԑ3/ԑ4, or ԑ4/ԑ4) and non-carriers (ԑ2/ԑ2, ԑ2/ԑ3, ԑ3, ԑ3). Two-thirds of our sample was non-APOE4 carriers, this result correlates with the proportion of APOE4 non-carriers found in other studies (Packard et al., 2007; Barnes et al., 2013). Pearson correlation coefficients were obtained for all dependent and independent variables. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research shows that lipid levels may be associated with cognitive function, particularly among women. We aimed to examine total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein (HDL), and HDL/LDL ratio in relation to cognitive performance, measured with six well-established cognitive domains and a composite cognitive score (CCS). In this cross-sectional study, biomarkers and neuropsychological assessment were available for 141 adults with MMSE scores ≥ 24 (mean age = 69 years, 47% female, mean education = 14.4 years) attending a neuropsychological evaluation. Ordinary least squares regressions were adjusted for age, gender, education, and depressive symptoms in Model 1 and also for apolipoprotein E4 (APOE4) status in Model 2. High-density lipoprotein cholesterol (HDL-C) was associated with better CCS (β = 0.24; p = 0.014). This association was significant among women (β = 0.30; p = 0.026) and not among men (β = 0.20; p = 0.124). HDL-C was also related to attention/working memory (β = 0.24; p = 0.021), again only among women (β = 0.37; p = 0.012) and not men (β = 0.15; p = 0.271). Adjusting for APOE4 yielded significance for high HDL-C and CCS (β = 0.24; p = 0.022). HDL-C was the main lipoprotein affecting cognitive function, with results somewhat more pronounced among women. Research should investigate the possibility of finding ways to boost HDL-C levels to potentially promote cognitive function.
    Full-text · Article · Mar 2015 · International Psychogeriatrics
  • Source
    • "The HPS investigators used brief telephone interviews to assess cognition and found no effect of simvastatin 40 mg OD versus placebo over the course of 5 years [39]. In the PROSPER study, which was of older people, the trialists did not report any benefits, on the basis of cognitive testing, from pravastatin 40 mg OD therapy over a mean course of 3.2 years [40]. However, their conclusions are not relevant to adults with Down syndrome, as the study participants were selected specifically for having vascular disease and/or vascular risk factors and not for Aβ overproduction. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid β (Aβ) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including potentially increasing brain amyloid clearance, making them plausible agents to reduce AD risk. Animal models, human observational studies, and small scale trials support this rationale, however, there are no AD primary prevention trials in Down syndrome adults. In this study we study aim to inform the design of a full-scale primary prevention trial. Methods/Design TOP-COG is a feasibility and pilot double-blind randomized controlled trial (RCT), with a nested qualitative study, conducted in the general community. About 60 Down syndrome adults, aged ≥50 will be included. The intervention is oral simvastatin 40mg at night for 12 months, versus placebo. The primary endpoint is recruitment and retention rates. Secondary endpoints are (1) tolerability and safety; (2) detection of the most sensitive neurocognitive instruments; (3) perceptions of Down syndrome adults and caregivers on whether to participate, and assessment experiences; (4) distributions of cognitive decline, adaptive behavior, general health/quality of life, service use, caregiver strain, and sample size implications; (5) whether Aβ42/Aβ40 is a cognitive decline biomarker. We will describe percentages recruited from each source, the number of contacts to achieve this, plus recruitment rate by general population size. We will calculate summary statistics with 90% confidence limits where appropriate, for each study outcome as a whole, by treatment group and in relation to baseline age, cognitive function, cholesterol and other characteristics. Changes over time will be summarized graphically. The sample size for a definitive RCT will be estimated under alternative assumptions. Discussion This study is important, as AD is a major problem for Down syndrome adults, for whom there are currently no effective preventions or treatments. It will also delineate the most suitable assessment instruments for this population. Recruitment of intellectually disabled adults is notoriously difficult, and we shall provide valuable information on this, informing future studies. Trial registration Current Controlled Trials ISRCTN Register ID: ISRCTN67338640 (17 November 2011)
    Full-text · Article · Jun 2014 · Trials
  • Source
    • "The ɛ3 variant is most prevalent, occurring in approximately 75–80% of the general population , whereas prevalence of ɛ2 and ɛ4 are approximately 7–8% and 14–15%, respectively (Schipper, 2011). The ɛ4 variant has been associated with disrupting neuroplastic brain mechanisms (Teter, 2004), and has also been implicated as a prominent risk factor for mild cognitive impairment (MCI; e.g., Brainerd, Reyna, Petersen, Smith, & Taub, 2011; Dixon et al., 2013), sporadic Alzheimer's disease (AD; Farrer et al., 1997), and other changes in cognitive functioning (Farlow et al., 2004; Packard et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The current study examined independent and interactive effects between Apolipoprotein E (APOE) genotype and two types of cognitively-stimulating lifestyle activities (CSLA)-integrated information processing (CSLA-II) and novel information processing (CSLA-NI)-on concurrent and longitudinal changes in cognition. Three-wave data across 6 years of follow-up from the Victoria Longitudinal Study (n=278; ages 55-94) and linear mixed model analyses were used to characterize the effects of APOE genotype and participation in CSLA-II and CSLA-NI in four cognitive domains. Significant CSLA effects on cognition were observed. More frequent participation in challenging activities (i.e., CSLA-NI) was associated with higher baseline scores on word recall, fact recall, vocabulary and verbal fluency. Conversely, higher participation in less cognitively-challenging activities (i.e., CSLA-II) was associated with lower scores on fact recall and verbal fluency. No longitudinal CSLA-cognition effects were found. Two significant genetic effects were observed. First, APOE moderated CSLA-II and CSLA-NI associations with baseline verbal fluency and fact recall scores. Second, APOE non-ɛ4 carriers' baseline performance were more likely to be moderated by CSLA participation, compared to APOE-ɛ4 carriers. Our findings suggest APOE may be a "plasticity" gene that makes individuals more or less amenable to the influence of protective factors such as CSLA. (JINS, 2014, 20, 1-9).
    Full-text · Article · May 2014 · Journal of the International Neuropsychological Society
Show more